Loading...
01/10 16:41
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates strong financial performance and reaffirmed guidance, suggesting stability. However, the Q&A reveals uncertainties, such as the lack of specifics on FYCOMPA's brand loyalty and AGAMREE's life cycle management, which could temper investor enthusiasm. The oncology portion of FIRDAPSE is more of a long-term story, and the impact of generics on FYCOMPA remains unclear. The market cap indicates a moderate reaction is likely, leading to a neutral stock price movement prediction.
Total Revenue $148.4 million, an increase of 15.3% year-over-year. Driven by strong demand for rare disease therapies, particularly FIRDAPSE and AGAMREE, and extended patient preference for FYCOMPA following generic entry.
Cash Position $689.9 million with no debt. Reflects strong cash flow generation and financial discipline.
FIRDAPSE Revenue $92.2 million, an increase of 16.2% year-over-year. Growth attributed to sustained demand, robust patient pool, and diagnostic efforts for Lambert-Eaton myasthenic syndrome (LEMS).
AGAMREE Revenue $32.4 million, a 115.2% increase year-over-year. Growth driven by conversion from prednisone and EMFLAZA, high patient retention, and adoption across DMD centers of excellence.
FYCOMPA Revenue $23.8 million, a decrease of 25.8% year-over-year. Decline due to generic entry, though mitigated by patient loyalty to the brand.
Net Income Before Taxes $71.0 million, a 24.2% increase year-over-year. Reflects strong revenue growth and operational efficiency.
GAAP Net Income $52.8 million or $0.42 per diluted share, a 20.3% increase year-over-year. Driven by revenue growth and cost management.
Non-GAAP Net Income $86.1 million or $0.68 per diluted share, compared to $71.1 million or $0.57 per diluted share in Q3 2024. Excludes amortization, stock-based compensation, and other adjustments.
Cost of Sales $22.7 million, compared to $19.3 million in Q3 2024. Increase due to royalties, particularly for AGAMREE.
Research and Development Expenses $2.7 million, compared to $3.3 million in Q3 2024. Decrease attributed to lower spending on ongoing AGAMREE studies.
Selling, General and Administrative Expenses $47.5 million, compared to $45.9 million in Q3 2024. Increase due to cancer-associated LEMS activities.
FIRDAPSE: Generated $92.2 million in revenue in Q3 2025, a 16.2% year-over-year increase. Positioned as the only evidence-based approved product in the U.S. for Lambert-Eaton myasthenic syndrome. Focused on expanding reach to undiagnosed cancer-associated LEMS patients, with 90% still undiagnosed.
AGAMREE: Generated $32.4 million in revenue in Q3 2025, a 115.2% year-over-year increase. Strong adoption across Duchenne Muscular Dystrophy (DMD) centers with 90% patient retention rate. Transitioning patients from prednisone and EMFLAZA, with growing prescriber engagement.
FYCOMPA: Generated $23.8 million in revenue in Q3 2025, a 25.8% year-over-year decrease due to generic competition. Despite this, stronger-than-expected performance led to raised full-year revenue guidance.
Cancer-associated LEMS: Focused on expanding VGCC antibody testing and streamlining diagnostic pathways. Updated NCCN guidelines now recommend VGCC antibody testing and amifampridine, potentially boosting market adoption.
Duchenne Muscular Dystrophy (DMD): AGAMREE adoption expanding across all DMD centers of excellence in the U.S., with strong payer alignment and prescriber engagement.
Revenue Growth: Total revenue for Q3 2025 reached $148.4 million, a 15.3% year-over-year increase. Full-year revenue guidance raised to $565-$585 million.
Cash Position: Ended Q3 2025 with $689.9 million in cash and no debt, enabling strategic investments and share repurchase program.
Share Buyback Program: Authorized a $200 million share repurchase program from October 2025 to December 2026.
Business Development: Evaluated over 100 opportunities since January 2025, focusing on rare disease therapies. Leveraging Catalyst Pathways for patient support and therapy optimization.
Intellectual Property (IP): Settled FIRDAPSE patent litigation with Lupin, delaying generic entry until February 2035. One pending case against Hetero USA, Inc., with trial set for March 2026.
Generic competition for FYCOMPA: The entry of generic versions of FYCOMPA tablets in Q2 2025 has already led to a 25.8% year-over-year revenue decrease for the product in Q3 2025. The company anticipates further revenue erosion as additional generics enter the market.
Undiagnosed cancer-associated LEMS patients: Approximately 90% of cancer-associated LEMS patients remain undiagnosed, representing a significant challenge in expanding the market for FIRDAPSE. Efforts to address this include updated guidelines and diagnostic pathways, but the scale of the issue remains a hurdle.
Patent litigation risks: The company is still engaged in a pending patent litigation case against Hetero USA, Inc., with a trial date set for March 2026. This ongoing legal issue could impact the company's ability to protect its intellectual property and long-term revenue streams.
Revenue dependency on FIRDAPSE: FIRDAPSE remains a major revenue driver, contributing $92.2 million in Q3 2025. Any disruptions in its market performance, such as competition or regulatory changes, could significantly impact the company's financial health.
Supply chain and royalty obligations for AGAMREE: AGAMREE's royalties increase as net sales grow, with a $12.5 million milestone payment required once annual net product revenue reaches $100 million. This could strain financial resources if sales growth is not sustained.
Regulatory and payer alignment for AGAMREE: While AGAMREE has shown strong adoption, its success depends on continued payer alignment and regulatory support. Any changes in these areas could hinder its market performance.
2025 Total Revenue Guidance: Catalyst raised its 2025 total revenue guidance to between $565 million and $585 million, reflecting strong performance across its portfolio.
FIRDAPSE Revenue Guidance: Catalyst expects full-year 2025 net product revenue for FIRDAPSE to be between $355 million and $360 million, driven by sustained organic growth and efforts to expand patient identification and diagnostic pathways.
AGAMREE Revenue Guidance: Catalyst raised its full-year 2025 net product revenue guidance for AGAMREE to a range of $105 million to $115 million, supported by strong adoption, patient retention, and prescriber engagement.
FYCOMPA Revenue Guidance: Catalyst increased its full-year 2025 net product revenue guidance for FYCOMPA to between $100 million and $110 million, despite anticipated revenue erosion from generic competition.
FIRDAPSE Growth Outlook: Catalyst anticipates sustained growth for FIRDAPSE through 2026 and beyond, driven by efforts to expand VGCC antibody testing, improve diagnostic pathways, and increase adoption in both idiopathic and cancer-associated LEMS markets.
AGAMREE Long-Term Study: Catalyst is actively enrolling patients in the SUMMIT study, a 5-year follow-up study to evaluate AGAMREE's long-term clinical safety and potential benefits on behavior, stature, bone health, and cardiovascular health.
Business Development Strategy: Catalyst continues to evaluate over 100 business development opportunities since January, aiming to expand its portfolio and leverage its infrastructure for rare disease therapies.
Share Buyback Program: Catalyst Pharmaceuticals announced a new share buyback program authorized by the Board of Directors. The program allows for the repurchase of up to $200 million of Catalyst's outstanding common stock. The buyback period is set between October 1, 2025, and December 31, 2026. The company stated that this program can be executed without impairing its business development strategy and aims to provide value to shareholders.
The earnings call summary indicates strong financial performance and reaffirmed guidance, suggesting stability. However, the Q&A reveals uncertainties, such as the lack of specifics on FYCOMPA's brand loyalty and AGAMREE's life cycle management, which could temper investor enthusiasm. The oncology portion of FIRDAPSE is more of a long-term story, and the impact of generics on FYCOMPA remains unclear. The market cap indicates a moderate reaction is likely, leading to a neutral stock price movement prediction.
The earnings call summary highlights strong financial performance, with significant revenue and net income growth. Product development is promising, with market expansion for AGAMREE and strategic initiatives for FIRDAPSE. The Q&A reassures continued growth and strategic initiatives, though some uncertainty remains in R&D and SG&A. The market cap suggests a moderate reaction. Overall, the company's robust financial metrics, market strategy, and optimistic guidance outweigh minor uncertainties, indicating a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
